These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 25836641)

  • 41. [Predictive factors and unfavorable prognostic factorial analysis of interstitial lung disease in patients with inflammatory myopathy].
    Li R; Li XP; Li XM; Wang GS; Qian L; Tao JH; Ma Y; Zhang H
    Zhonghua Yi Xue Za Zhi; 2012 Sep; 92(33):2335-8. PubMed ID: 23158563
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Idiopathic inflammatory myopathies: current trends in pathogenesis, clinical features, and up-to-date treatment recommendations.
    Ernste FC; Reed AM
    Mayo Clin Proc; 2013 Jan; 88(1):83-105. PubMed ID: 23274022
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognostic factors of idiopathic inflammatory myopathies complicated with interstitial lung disease: protocol for a systematic review and meta-analysis.
    Kamiya H; Panlaqui OM; Izumi S; Sozu T
    BMJ Open; 2016 Nov; 6(11):e012744. PubMed ID: 27856478
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Management of interstitial lung disease (ILD) in myositis syndromes: A practical guide for clinicians.
    Mehta P; Aggarwal R; Porter JC; Gunawardena H
    Best Pract Res Clin Rheumatol; 2022 Jun; 36(2):101769. PubMed ID: 35840503
    [TBL] [Abstract][Full Text] [Related]  

  • 45. ADAM-17 is expressed in the inflammatory myopathy and is involved with interstitial lung disease.
    Nishimi A; Isozaki T; Nishimi S; Ishii S; Tokunaga T; Furuya H; Wakabayashi K; Kasama T
    Clin Rheumatol; 2018 Apr; 37(4):1017-1024. PubMed ID: 29411180
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cardiological features in idiopathic inflammatory myopathies.
    Bazzani C; Cavazzana I; Ceribelli A; Vizzardi E; Dei Cas L; Franceschini F
    J Cardiovasc Med (Hagerstown); 2010 Dec; 11(12):906-11. PubMed ID: 20625308
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [The cutting-edge of medicine: progress of autoantibodies in polymyositis and dermatomyositis-biomarker for myositis-associated interstitial lung disease].
    Mimori T; Hosono Y; Nakashima R
    Nihon Naika Gakkai Zasshi; 2012 Feb; 101(2):488-94. PubMed ID: 22523822
    [No Abstract]   [Full Text] [Related]  

  • 48. Treatment of idiopathic inflammatory myopathies.
    Amato AA; Griggs RC
    Curr Opin Neurol; 2003 Oct; 16(5):569-75. PubMed ID: 14501840
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Interstitial lung disease in connective tissue disorders.
    Fischer A; du Bois R
    Lancet; 2012 Aug; 380(9842):689-98. PubMed ID: 22901890
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease.
    Gono T; Kaneko H; Kawaguchi Y; Hanaoka M; Kataoka S; Kuwana M; Takagi K; Ichida H; Katsumata Y; Ota Y; Kawasumi H; Yamanaka H
    Rheumatology (Oxford); 2014 Dec; 53(12):2196-203. PubMed ID: 24970922
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Review series: Aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ?
    de Lauretis A; Veeraraghavan S; Renzoni E
    Chron Respir Dis; 2011; 8(1):53-82. PubMed ID: 21339375
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Lung is also involved in juvenile dermatomyositis].
    Pouessel G; Thumerelle C; Nève V; Santangelo T; Flammarion S; Pruvot I; Tillie-Leblond I; Deschildre A
    Rev Med Interne; 2014 Jul; 35(7):461-5. PubMed ID: 24856457
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Establishment of an ELISA to detect anti-glycyl-tRNA synthetase antibody (anti-EJ), a serological marker of dermatomyositis/polymyositis and interstitial lung disease.
    Hane H; Muro Y; Watanabe K; Ogawa Y; Sugiura K; Akiyama M
    Clin Chim Acta; 2014 Apr; 431():9-14. PubMed ID: 24508626
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies.
    Krystufková O; Vallerskog T; Helmers SB; Mann H; Putová I; Belácek J; Malmström V; Trollmo C; Vencovsky J; Lundberg IE
    Ann Rheum Dis; 2009 Jun; 68(6):836-43. PubMed ID: 18628284
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Therapeutic strategies in idiopatic inflammatory myopathies].
    Chakour R; Leimgruber A; Bart PA; Spertini F
    Rev Med Suisse; 2009 Apr; 5(199):812-8. PubMed ID: 19441746
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inflammatory myopathies: clinical, diagnostic and therapeutic aspects.
    Mastaglia FL; Garlepp MJ; Phillips BA; Zilko PJ
    Muscle Nerve; 2003 Apr; 27(4):407-25. PubMed ID: 12661042
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Myositis-associated interstitial lung disease: a comprehensive approach to diagnosis and management.
    Hallowell RW; Paik JJ
    Clin Exp Rheumatol; 2022 Feb; 40(2):373-383. PubMed ID: 33769263
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antisynthetase syndrome with refractory lung involvement and myositis successfully treated with double filtration plasmapheresis.
    Bozkirli DE; Kozanoglu I; Bozkirli E; Yucel E
    J Clin Apher; 2013 Dec; 28(6):422-5. PubMed ID: 23908096
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Therapies for interstitial lung disease: past, present and future.
    Kim R; Meyer KC
    Ther Adv Respir Dis; 2008 Oct; 2(5):319-38. PubMed ID: 19124380
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Idiopathic inflammatory myopathies: a treatment update.
    Oddis CV
    Curr Rheumatol Rep; 2003 Dec; 5(6):431-6. PubMed ID: 14609487
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.